Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Mar 15;60(6):970.
doi: 10.1093/cid/ciu1147. Epub 2014 Dec 19.

Analysis of Green Light Committee implementation and acquisition of second-line drug resistance

John Z Metcalfe  1 , Eric Vittinghoff  2 , Philip C Hopewell  1
Affiliations
Comment

Analysis of Green Light Committee implementation and acquisition of second-line drug resistance

John Z Metcalfe et al. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply to Soman et al, Alffenaar et al, Metcalfe et al, and Raoult.
    Cegielski JP, Chen MP, Tupasi TE, Leimane V, Volchenkov GV; Global Preserving Effective TB Treatment Study Investigators. Cegielski JP, et al. Clin Infect Dis. 2015 Mar 15;60(6):971-3. doi: 10.1093/cid/ciu1150. Epub 2014 Dec 19. Clin Infect Dis. 2015. PMID: 25527654 Free PMC article. No abstract available.

Comment on

  • Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.
    Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S; Global Preserving Effective TB Treatment Study (PETTS) Investigators. Cegielski JP, et al. Clin Infect Dis. 2014 Oct 15;59(8):1049-63. doi: 10.1093/cid/ciu572. Epub 2014 Jul 23. Clin Infect Dis. 2014. PMID: 25057101 Free PMC article.

References

    1. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049–63. - PMC - PubMed
    1. Gupta R, Irwin A, Raviglione MC, Kim JY. Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis. Lancet. 2004;363:320–4. - PubMed
    1. Kim JY, Mukherjee JS, Rich ML, Mate K, Bayona J, Becerra MC. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis (Edinb) 2003;83:59–65. - PubMed
    1. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144:650–9. - PubMed
    1. Koh WJ, Lee SH, Kang YA, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188:858–64. - PubMed

MeSH terms

Substances

LinkOut - more resources